Nasdaq · CIK 0001678660
PRLD Prelude Therapeutics Inc
Insider trading from SEC Form 4. Last filing Jun 13, 2025. Close $3.89 on Oct 9, 2026, +227% from the 52-week low and -41% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Price and insider trades, last year
PRLDOct 9, 2026 · close 3.89
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Prelude Therapeutics Inc, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 29Weak | Andrew Combs Chief Chemistry Officer buy | $69k 100,000 shares | +26% | - | |
| 45Moderate | Andrew Combs Chief Chemistry Officer buy | $86k 63,075 shares | +20% | - | |
| 47Moderate | Bryant David Lim CLO, Interim CFO, Corp Sec. buy | $23k 25,000 shares | +1042% | - | |
| 53Moderate | Krishna Vaddi CEO buy | $99k 106,888 shares | +10% | - |
Transactions
The last 21 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 12, 2025 | Martin Babler director | AGrant or award Director Stock Option (Right to Buy)derivative | +38,000 | $0.00 | $0 | 38,000 | Jun 13, 2025 |
| Jun 12, 2025 | David P Bonita director, owner | AGrant or award Director Stock Option (Right to Buy)derivative | +38,000 | $0.00 | $0 | 38,000 | Jun 13, 2025 |
| Jun 12, 2025 | Mardi Dier director | AGrant or award Director Stock Option (Right to Buy)derivative | +38,000 | $0.00 | $0 | 38,000 | Jun 13, 2025 |
| Jun 12, 2025 | Paul A Friedman director | AGrant or award Director Stock Option (Right to Buy)derivative | +38,000 | $0.00 | $0 | 38,000 | Jun 13, 2025 |
| Jun 12, 2025 | Victor Sandor director | AGrant or award Director Stock Option (Right to Buy)derivative | +38,000 | $0.00 | $0 | 38,000 | Jun 13, 2025 |
| Jun 12, 2025 | Baker Bros. Advisors LP director, owner | AGrant or award Non- Qualified Stock Option (right to buy)derivativeindirect: See Footnotes | +76,000 | $0.00 | $0 | 76,000 | Jun 13, 2025 |
| Jun 12, 2025 | Baker Bros. Advisors LP director, owner | AGrant or award Non- Qualified Stock Option (right to buy)derivativeindirect: See Footnotes | +76,000 | $0.00 | $0 | 76,000 | Jun 13, 2025 |
| Apr 4, 2025 | Jane Huang President, CMO | MOption exercise Common Stock | +9,375 | - | - | 78,232 | Apr 7, 2025 |
| Apr 4, 2025 | Jane Huang President, CMO | FTax withholding Common Stock | -3,355 | $0.68 | $2,265 | 74,877 | Apr 7, 2025 |
| Apr 4, 2025 | Jane Huang President, CMO | MOption exercise Restricted Stock Unitderivative | -9,375 | $0.00 | $0 | 37,500 | Apr 7, 2025 |
| Mar 25, 2025 | Andrew Combs Chief Chemistry Officer | POpen-market purchase Common Stock | +100,000 | $0.69 | $69k | 480,123 | Mar 27, 2025 |
| Feb 4, 2025 | Andrew Combs Chief Chemistry Officer | AGrant or award Employee Stock Option (right to buy)derivative | +175,000 | $0.00 | $0 | 175,000 | Feb 5, 2025 |
| Feb 4, 2025 | Jane Huang President, CMO | AGrant or award Employee Stock Option (right to buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Feb 5, 2025 |
| Jan 4, 2025 | Jane Huang President, CMO | MOption exercise Common Stock | +9,375 | - | - | 72,716 | Jan 7, 2025 |
| Jan 4, 2025 | Jane Huang President, CMO | FTax withholding Common Stock | -3,859 | $1.39 | $5,364 | 68,857 | Jan 7, 2025 |
| Jan 4, 2025 | Jane Huang President, CMO | MOption exercise Restricted Stock Unitderivative | +9,375 | $0.00 | $0 | 46,875 | Jan 7, 2025 |
| Dec 20, 2024 | Andrew Combs Chief Chemistry Officer | POpen-market purchase Common Stock | +3,075 | $1.15 | $3,536 | 317,623 | Dec 26, 2024 |
| Dec 23, 2024 | Andrew Combs Chief Chemistry Officer | POpen-market purchase Common Stock | +60,000 | $1.37 | $82k | 377,623 | Dec 26, 2024 |
| Dec 19, 2024 | Bryant David Lim CLO, Interim CFO, Corp Sec. | POpen-market purchase Common Stock | +25,000 | $0.91 | $23k | 27,400 | Dec 20, 2024 |
| Dec 18, 2024 | Krishna Vaddi CEO | POpen-market purchase Common Stock | +100,000 | $0.93 | $93k | 1,167,275 | Dec 20, 2024 |
| Dec 19, 2024 | Krishna Vaddi CEO | POpen-market purchase Common Stockindirect: See footnote | +6,888 | $0.89 | $6,116 | 127,553 | Dec 20, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Baker Bros. Advisors LPdirector, owner, other
- Martin Bablerdirector, ceo, president, chair, officer
- David P Bonitadirector, owner
- Andrew CombsChief Chemistry Officer
- Mardi Dierdirector, cfo, officer
- Paul A Friedmandirector
- Jane HuangPresident, CMO
- Bryant David LimCLO, Interim CFO, Corp Sec.
- Victor Sandordirector
- Krishna VaddiCEO
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.